Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours
Christian D Fankhauser, Ailsa J Christiansen, Christian Rothermundt, Richard Cathomas, Marian S Wettstein, Nico C Grossmann, Josias B Grogg, Arnoud J Templeton, Anita Hirschi-Blickenstorfer, Anja Lorch, Silke Gillessen, Holger Moch, Joerg Beyer & Thomas Hermanns
MiR-371a-3p levels immediately post orchiectomy are not predictive for recurrences and unfortunately cannot support decision-making for AS vs. adjuvant treatment. However, miR-371a-3p detects recurrences reliably and earlier than standard follow-up investigations. If this can be confirmed in larger cohorts, monitoring miR-371a-3p could replace surveillance imaging in seminomatous GCT and reduce the amount of imaging in non-seminomatous GCT. Earlier detection of disease recurrence may also reduce the overall treatment burden.
|citation||Fankhauser C D, Christiansen A J, Rothermundt C, Cathomas R, Wettstein M S, Grossmann N C, Grogg J B, Templeton A J, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2021;.|
|type||journal paper/review (English)|
|date of publishing||15-12-2021|
|journal title||Br J Cancer|